INTRODUCTION: The immunosuppressive roles of galectin-3 (Gal-3) in carcinogenesis make this lectin an attractive target for pharmacological inhibition in immunotherapy. Although current clinical immunotherapies appear promising in the treatment of solid tumors, their efficacy is significantly weakened by the hostile immunosuppressive tumor microenvironment (TME). Gal-3, a prominent TME modulator, efficiently subverts the elimination of cancer, either directly by inducing apoptosis of immune cells or indirectly by binding essential effector molecules, such as interferon-gamma (IFNγ). METHODS: N-(2-Hydroxypropyl)methacrylamide (HPMA)-based glycopolymers bearing poly-N-acetyllactosamine-derived tetrasaccharide ligands of Gal-3 were designed, synthesized, and characterized using high-performance liquid chromatography, dynamic light scattering, UV-Vis spectrophotometry, gel permeation chromatography, nuclear magnetic resonance, high-resolution mass spectrometry and CCK-8 assay for evaluation of glycopolymer non-toxicity. Pro-immunogenic effects of purified glycopolymers were tested by apoptotic assay using flow cytometry, competitive ELISA, and in vitro cell-free INFγ-based assay. RESULTS: All tested glycopolymers completely inhibited Gal-3-induced apoptosis of monocytes/macrophages, of which the M1 subtype is responsible for eliminating cancer cells during immunotherapy. Moreover, the glycopolymers suppressed Gal-3-induced capture of glycosylated IFNγ by competitive inhibition to Gal-3 carbohydrate recognition domain (CRD), which enables further inherent biological activities of this effector, such as differentiation of monocytes into M1 macrophages and repolarization of M2-macrophages to the M1 state. CONCLUSION: The prepared glycopolymers are promising inhibitors of Gal-3 and may serve as important supportive anti-cancer nanosystems enabling the infiltration of proinflammatory macrophages and the reprogramming of unwanted M2 macrophages into the M1 subtype.

Department of Biological Models Institute of Macromolecular Chemistry of the Czech Academy of Sciences Prague Czech Republic

Department of Biomedical Polymers Institute of Macromolecular Chemistry of the Czech Academy of Sciences Prague Czech Republic

Department of Genetics and Microbiology Faculty of Science Charles University Prague Czech Republic

Department of Health Care Disciplines and Population Protection Faculty of Biomedical Engineering Czech Technical University Prague Kladno Czech Republic

Laboratory of Biotransformation Institute of Microbiology of the Czech Academy of Sciences Prague Czech Republic

Zobrazit více v PubMed

Cheng S, Li Z, Gao R, et al. A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells. PubMed DOI

Kwart D, He J, Srivatsan S, et al. Cancer cell-derived type I interferons instruct tumor monocyte polarization. PubMed DOI

Chen S, Saeed A, Liu Q, et al. Macrophages in immunoregulation and therapeutics. PubMed DOI PMC

Chen X, Dou J, Fu Z, et al. Macrophage M1 polarization mediated via the IL-6/STAT3 pathway contributes to apical periodontitis induced by Porphyromonas gingivalis. PubMed DOI PMC

Watkins SK, Egilmez NK, Suttles J, Stout RD. IL-12 rapidly alters the functional profile of tumor-associated and tumor-infiltrating macrophages in vitro and in vivo. PubMed DOI

Ahmed H, AlSadek DM. Galectin-3 as a Potential Target to Prevent Cancer Metastasis. PubMed DOI PMC

Funasaka T, Raz A, Nangia-Makker P. Galectin-3 in angiogenesis and metastasis. PubMed DOI PMC

Huang Y, Wang HC, Zhao J, Wu MH, Shih TC. Immunosuppressive Roles of Galectin-1 in the Tumor Microenvironment. PubMed DOI PMC

Rudjord-Levann AM, Ye Z, Hafkenscheid L, et al. Galectin-1 induces a tumor-associated macrophage phenotype and upregulates indoleamine 2,3-dioxygenase-1. PubMed DOI PMC

Barrueto L, Caminero F, Cash L, Makris C, Lamichhane P, Deshmukh RR. Resistance to Checkpoint Inhibition in Cancer Immunotherapy. PubMed DOI PMC

Jia W, Kidoya H, Yamakawa D, Naito H, Takakura N. Galectin-3 accelerates M2 macrophage infiltration and angiogenesis in tumors. PubMed DOI

Gordon-Alonso M, Hirsch T, Wildmann C, van der Bruggen P. Galectin-3 captures interferon-gamma in the tumor matrix reducing chemokine gradient production and T-cell tumor infiltration. PubMed DOI PMC

Wu C, Xue Y, Wang P, et al. IFN-gamma primes macrophage activation by increasing phosphatase and tensin homolog via downregulation of miR-3473b. PubMed DOI

Bhat P, Leggatt G, Waterhouse N, Frazer IH. Interferon-gamma derived from cytotoxic lymphocytes directly enhances their motility and cytotoxicity. PubMed DOI PMC

Mabbitt J, Holyer ID, Roper JA, et al. Resistance to anti-PD-1/anti-PD-L1: galectin-3 inhibition with GB1211 reverses galectin-3-induced blockade of pembrolizumab and atezolizumab binding to PD-1/PD-L1. PubMed DOI PMC

Filipova M, Bojarova P, Rodrigues Tavares M, et al. Glycopolymers for Efficient Inhibition of Galectin-3: in Vitro Proof of Efficacy Using Suppression of T Lymphocyte Apoptosis and Tumor Cell Migration. PubMed DOI

Bumba L, Laaf D, Spiwok V, Elling L, Kren V, Bojarova P. Poly- PubMed DOI PMC

Laaf D, Bojarova P, Pelantova H, Kren V, Elling L. Tailored Multivalent Neo-Glycoproteins: synthesis, Evaluation, and Application of a Library of Galectin-3-Binding Glycan Ligands. PubMed DOI

Vasicek T, Spiwok V, Cerveny J, et al. Regioselective 3- PubMed DOI

Collins PM, Bum-Erdene K, Yu X, Blanchard H. Galectin-3 interactions with glycosphingolipids. PubMed DOI

Šimonová A, Kupper CE, Böcker S, et al. Chemo-enzymatic synthesis of LacdiNAc dimers of varying length as novel galectin ligands. DOI

Heine V, Hovorkova M, Vlachova M, et al. Immunoprotective neo-glycoproteins: chemoenzymatic synthesis of multivalent glycomimetics for inhibition of cancer-related galectin-3. PubMed DOI

Craft KM, Townsend SD. Synthesis of lacto- PubMed DOI PMC

Bandara MD, Stine KJ, Demchenko AV. The chemical synthesis of human milk oligosaccharides: Lacto- PubMed DOI PMC

Nekvasilova P, Kulik N, Kotik M, et al. Mutation Hotspot for Changing the Substrate Specificity of beta- PubMed DOI PMC

Ulbrich K, Hola K, Subr V, Bakandritsos A, Tucek J, Zboril R. Targeted Drug Delivery with Polymers and Magnetic Nanoparticles: covalent and Noncovalent Approaches, Release Control, and Clinical Studies. PubMed DOI

Chytil P, Koziolova E, Etrych T, Ulbrich K. HPMA Copolymer-Drug Conjugates with Controlled Tumor-Specific Drug Release. PubMed DOI

Chytil P, Kostka L, Etrych T. HPMA Copolymer-Based Nanomedicines in Controlled Drug Delivery. PubMed DOI PMC

Rihova B, Kovar M. Immunogenicity and immunomodulatory properties of HPMA-based polymers. PubMed DOI

Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. PubMed DOI

Quan L, Zhang Y, Crielaard BJ, et al. Nanomedicines for inflammatory arthritis: head-to-head comparison of glucocorticoid-containing polymers, micelles, and liposomes. PubMed DOI PMC

Dozono H, Yanazume S, Nakamura H, et al. HPMA Copolymer-Conjugated Pirarubicin in Multimodal Treatment of a Patient with Stage IV Prostate Cancer and Extensive Lung and Bone Metastases. PubMed DOI

Duncan R, Vicent MJ. Do HPMA copolymer conjugates have a future as clinically useful nanomedicines? A critical overview of current status and future opportunities. PubMed DOI

Seymour LW, Ferry DR, Kerr DJ, et al. Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. PubMed DOI

Bojarová P, Chytil P, Mikulová B, et al. Glycan-decorated HPMA copolymers as high-affinity lectin ligands. 10.1039/C7PY00271H. DOI

Bojarova P, Tavares MR, Laaf D, et al. Biocompatible glyconanomaterials based on HPMA-copolymer for specific targeting of galectin-3. PubMed DOI PMC

Tavares MR, Blahova M, Sedlakova L, et al. High-Affinity PubMed DOI

Vrbata D, Filipova M, Tavares MR, et al. Glycopolymers Decorated with 3- PubMed DOI

Fischoder T, Wahl C, Zerhusen C, Elling L. Repetitive Batch Mode Facilitates Enzymatic Synthesis of the Nucleotide Sugars UDP-Gal, UDP-GlcNAc, and UDP-GalNAc on a Multi-Gram Scale. PubMed DOI

Sauerzapfe B, Namdjou DJ, Schumacher T, et al. Characterization of recombinant fusion constructs of human β1,4-galactosyltransferase 1 and the lipase pre-propeptide from Staphylococcus hyicus. DOI

Sauerzapfe B, Krenek K, Schmiedel J, et al. Chemo-enzymatic synthesis of poly-N-acetyllactosamine (poly-LacNAc) structures and their characterization for CGL2-galectin-mediated binding of ECM glycoproteins to biomaterial surfaces. PubMed DOI

Kupper CE, Rosencrantz RR, Henssen B, et al. Chemo-enzymatic modification of poly- PubMed DOI PMC

Henze M, You DJ, Kamerke C, et al. Rational design of a glycosynthase by the crystal structure of β-galactosidase from PubMed DOI

Hirabayashi J, Kasai K. Effect of amino acid substitution by sited-directed mutagenesis on the carbohydrate recognition and stability of human 14-kDa beta-galactoside-binding lectin. PubMed DOI

Bojarova P, Kulik N, Hovorkova M, Slamova K, Pelantova H, Kren V. The β- PubMed DOI PMC

Hovorková M, Kulik N, Konvalinková D, Petrásková L, Křen V, Bojarová P. Mutagenesis of Catalytic Nucleophile of β-Galactosidase Retains Residual Hydrolytic Activity and Affords a Transgalactosidase. DOI

Rech C, Rosencrantz RR, Křenek K, et al. Combinatorial One-Pot Synthesis of Poly-N-acetyllactosamine Oligosaccharides with Leloir-Glycosyltransferases. DOI

Šubr V, Ulbrich K. Synthesis and properties of new DOI

Chytil P, Etrych T, Kriz J, Subr V, Ulbrich K. PubMed DOI

Etrych T, Subr V, Strohalm J, Sirova M, Rihova B, Ulbrich K. HPMA copolymer-doxorubicin conjugates: the effects of molecular weight and architecture on biodistribution and in vivo activity. PubMed DOI

Laaf D, Bojarová P, Mikulová B, Pelantová H, Křen V, Elling L. Two-Step Enzymatic Synthesis of β-d- DOI

Lundquist JJ, Toone EJ. The Cluster Glycoside Effect. PubMed DOI

Sedlar A, Vrbata D, Pokorna K, et al. Glycopolymer Inhibitors of Galectin-3 Suppress the Markers of Tissue Remodeling in Pulmonary Hypertension. PubMed DOI PMC

Konvalinkova D, Dolnicek F, Hovorkova M, et al. Glycocalix[4]arenes and their affinity to a library of galectins: the linker matters. PubMed DOI

Mullerova M, Hovorkova M, Zavodna T, et al. Lactose-Functionalized Carbosilane Glycodendrimers Are Highly Potent Multivalent Ligands for Galectin-9 Binding: increased Glycan Affinity to Galectins Correlates with Aggregation Behavior. PubMed DOI PMC

Jiang J, Mei J, Ma Y, et al. Tumor hijacks macrophages and microbiota through extracellular vesicles. PubMed DOI PMC

Feng Y, Ye Z, Song F, He Y, Liu J. The Role of TAMs in Tumor Microenvironment and New Research Progress. PubMed DOI PMC

Tran TH, Rastogi R, Shelke J, Amiji MM. Modulation of Macrophage Functional Polarity towards Anti-Inflammatory Phenotype with Plasmid DNA Delivery in CD44 Targeting Hyaluronic Acid Nanoparticles. PubMed DOI PMC

Chamberlain LM, Godek ML, Gonzalez-Juarrero M, Grainger DW. Phenotypic non-equivalence of murine (monocyte-) macrophage cells in biomaterial and inflammatory models. PubMed DOI PMC

Sturgill ER, Rolig AS, Linch SN, et al. Galectin-3 inhibition with belapectin combined with anti-OX40 therapy reprograms the tumor microenvironment to favor anti-tumor immunity. PubMed DOI PMC

Stillman BN, Hsu DK, Pang M, et al. Galectin-3 and galectin-1 bind distinct cell surface glycoprotein receptors to induce T cell death. PubMed DOI

Nangia-Makker P, Nakahara S, Hogan V, Raz A. Galectin-3 in apoptosis, a novel therapeutic target. PubMed DOI PMC

Tekin C, Aberson HL, Bijlsma MF, Spek CA. Early macrophage infiltrates impair pancreatic cancer cell growth by TNF-alpha secretion. PubMed DOI PMC

Maccio A, Gramignano G, Cherchi MC, Tanca L, Melis L, Madeddu C. Role of M1-polarized tumor-associated macrophages in the prognosis of advanced ovarian cancer patients. PubMed DOI PMC

Zheng Y, Han Y, Sun Q, Li Z. Harnessing anti-tumor and tumor-tropism functions of macrophages via nanotechnology for tumor immunotherapy. PubMed DOI PMC

Guo Y, Shen R, Yang K, et al. RNF8 enhances the sensitivity of PD-L1 inhibitor against melanoma through ubiquitination of galectin-3 in stroma. PubMed DOI PMC